The Department of Health and Human Services’ Office for Civil Rights is advising clinicians to take a closer look at their legacy IT systems and devices.
All articles by Jody Charnow
In a phase 3 trial of men with metastatic castration-resistant prostate cancer and altered DNA repair genes, olaparib-treated patients had significantly longer radiographic progression-free survival compared with enzalutamide or abiraterone recipients.
Latest News Your top articles for TuesdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses